Inmune Bio grants director 100,000 options

The options vest monthly over three years, beginning one month after the grant date, and have a $2.33-per-share exercise price.

Rhea-AI Filing Summary

Inmune Bio, Inc. director Ronnie Duane Clark received an initial award of options covering 100,000 common shares on September 15, 2026, under the Third Amended and Restated 2021 Stock Incentive Plan. The options have a $2.33-per-share exercise price and vest in 36 equal monthly installments over three years, beginning one month after grant; full vesting occurs on the third anniversary. They expire September 14, 2036. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider Clark Ronnie Duane

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options F1	100,000	$0.00	$0.00

Holdings After Transaction: Stock Options — 100,000 contracts (Direct)

Footnotes (1)

1. F1. Represent an initial award of options in consideration for the Reporting Person's service to the Board of Directors of INmune Bio, Inc. Granted pursuant to the Issuer's Third Amended and Restated 2021 Stock Incentive Plan. The options will vest in 36 equal installments over three (3) years (1/36 per month) beginning one month after the grant date until the option is 100% vested which shall occur on the three-year anniversary of the date of grant.

Key Figures

Options awarded: 100,000 options covering common shares Exercise price: $2.33 per share Vesting installments: 36 equal monthly installments +2 more

5 metrics

Options awarded 100,000 options covering common shares Initial award dated September 15, 2026

Exercise price $2.33 per share Awarded options

Vesting installments 36 equal monthly installments Beginning one month after the grant date

Vesting period 3 years Full vesting occurs on the third anniversary of the grant date

Expiration date September 14, 2036 Options awarded September 15, 2026

Key Terms

Stock Options, exercise price, vest, Third Amended and Restated 2021 Stock Incentive Plan

4 terms

Stock Options financial

"initial award of options"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"exercise price of $2.33 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest technical

"vest in 36 equal installments over three (3) years"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Third Amended and Restated 2021 Stock Incentive Plan financial

"Granted pursuant to the Issuer's Third Amended and Restated 2021 Stock Incentive Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Inmune Bio (INMB) director Ronnie Duane Clark receive?

He received an initial award of options covering 100,000 common shares on September 15, 2026, under the Third Amended and Restated 2021 Stock Incentive Plan.

What is the exercise price for the INMB stock options?

The options have an exercise price of $2.33 per share.

How do the Inmune Bio (INMB) options vest?

They vest in 36 equal monthly installments over three years, beginning one month after the grant date. Full vesting occurs on the third anniversary of the grant date.

When do the INMB options expire?

The options expire on September 14, 2036.

Was the Inmune Bio (INMB) award reported under a Rule 10b5-1 plan?

No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/23/2026 - 06:06 AM Accepted by SEC EDGAR 09/23/2026 - 06:05 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clark Ronnie Duane

(Last) (First) (Middle)

C/O INMUNE BIO INC.

225 NE MIZNER BLVD., SUITE 640

(Street)

BOCA RATON FLORIDA 33432

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inmune Bio, Inc. [ INMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$2.33	09/15/2026		A		100,000		(1)	09/14/2036	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. Represent an initial award of options in consideration for the Reporting Person's service to the Board of Directors of INmune Bio, Inc. Granted pursuant to the Issuer's Third Amended and Restated 2021 Stock Incentive Plan. The options will vest in 36 equal installments over three (3) years (1/36 per month) beginning one month after the grant date until the option is 100% vested which shall occur on the three-year anniversary of the date of grant.

	/s/ R. Duane Clark	09/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)